Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

Delayed Quote. Delayed  - 10/25 08:57:35 pm
12.85 USD   -1.91%
10/19 NEKTAR THERAPEU : Prices Public Offering of Shares of Common Stock
10/17 NEKTAR THERAPEU : Announces Public Offering of Shares of Common Stoc..
09/27 NEKTAR THERAPEU : to Host Investor & Analyst Conference Call to Disc..
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
10/19/2016 | 11:03pm CEST

Item 1.01 Entry into a Material Definitive Agreement.

On October 18, 2016, Nektar Therapeutics, a Delaware corporation ("Nektar"), entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC ("J.P. Morgan"), as representative of the several underwriters named therein (the "Underwriters"), relating to the issuance and sale of 13,000,000 shares (the "Firm Shares") of common stock, par value $0.0001 per share, of Nektar. The price to the public in this offering is $13.50 per share, and the Underwriters agreed to purchase the Firm Shares from Nektar pursuant to the Underwriting Agreement at a price of $12.69 per share.

In addition, under the terms of the Underwriting Agreement, Nektar granted the Underwriters an option, exercisable for 30 days after October 18, 2016, to purchase up to 1,950,000 additional shares of common stock (the "Additional Shares" and collectively with the Firm Shares, the "Shares") at a price of $12.69 per share.

The net proceeds to Nektar from the issuance and sale of the Firm Shares are expected to be approximately $164.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Nektar.

The offering is expected to close on or about October 24, 2016, subject to customary closing conditions set forth in the Underwriting Agreement. J.P. Morgan is acting as the lead book-running manager. Jefferies LLC and Piper Jaffray & Co. are acting as book-running managers. William Blair & Company, L.L.C. is acting as lead manager for the offering, and Brean Capital, BTIG, LLC, Janney Montgomery Scott, Ladenburg Thalmann & Co. Inc. and Roth Capital Partners, LLC are acting as co-managers for the offering. The offering is being made pursuant to the effective registration statement on Form S-3ASR (File No. 333-193454) filed by Nektar with the Securities and Exchange Commission on January 21, 2014 and a prospectus supplement dated October 18, 2016 thereunder.

The Underwriting Agreement contains customary representations, warranties and covenants of Nektar, customary conditions to closing, indemnification obligations of Nektar and the Underwriters (including for liabilities under the Securities Act of 1933, as amended) and termination and other provisions customary for transactions of this nature. The representations, warranties and covenants of Nektar contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, are solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. Investors are not third-party beneficiaries under the Underwriting Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of Nektar.

The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K. A copy of the opinion of Sidley Austin LLP relating to the legality of the issuance and sale of the Shares in the offering is attached as Exhibit 5.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

           No.     Description

          1.1      Underwriting Agreement dated as of October 18, 2016

          5.1      Opinion of Sidley Austin LLP

         23.1      Consent of Sidley Austin LLP (included in Exhibit 5.1)


© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
10/19 NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Financial Stat..
10/19 NEKTAR THERAPEUTICS : Prices Public Offering of Shares of Common Stock
10/17 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Regulation ..
10/17 NEKTAR THERAPEUTICS : Announces Public Offering of Shares of Common Stock
10/06 BRISTOL MYERS SQUIBB : and Nektar Therapeutics Announce Oncology Clinical Collab..
09/27 NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD ..
09/27 NEKTAR THERAPEUTICS : to Host Investor & Analyst Conference Call to Discuss New ..
09/15 NEKTAR THERAPEUTICS : Researchers Submit Patent Application, "Self-Sealing T-Pie..
08/11 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
08/04 NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
08:05pDJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
10/19 Nektar prices equity offering at $13.50; shares down 3% premarket
10/17 After Hours Gainers / Losers
10/17 Nektar launches $175M equity offering
10/05 Synergy Pharmaceuticals Getting Closer To 'Go Time'
Financials ($)
Sales 2016 169 M
EBIT 2016 -113 M
Net income 2016 -146 M
Debt 2016 82,0 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 12,1x
EV / Sales 2017 10,3x
Capitalization 1 960 M
More Financials
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 8
Average target price 21,0 $
Spread / Average Target 60%
Consensus details
EPS Revisions
More Estimates Revisions
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 691
LONZA GROUP AG13.37%9 614
ALKERMES PLC-28.58%8 592
More Results